Multicenter Phase III Study Efficacy of mAb Treatment for Ventilator-Associated Pneumonia (VAP)

Case Study

About the Case Study

Allucent was contracted to assess a monoclonal antibody (mAb) treatment for Ventilator-Associated Pneumonia (VAP) due to Staphylococcus aureus (S. aureus) in tandem with standard of care (SOC) antibiotic therapy to determine efficacy, safety, and tolerability of proposed treatment. This made the patient targeting complex and narrow, and Allucent still delivered. 

Program Overview: Phase 3

Indication: Multicenter Phase 3 Study Efficacy of mAb Treatment for Ventilator-Associated Pneumonia (VAP) with SOC Antibiotics

Sites & Locations: 160 sites, 20+ countries

Allucent Services:

  • Feasibility & Site Solutions
  • Project Management
  • Clinical Operations & Trial Management
  • Data Management
  • Medical Affairs & Pharmacovigilance
  • Patient Engagement Services
  • Biostatistics
  • Medical Writing
  • Quality Assurance


DOWNLOAD RESOURCE